An2 Therapeutics (ANTX) closed at $4.55 on November 13, 2026, up 2.5% from the previous close, on volume of 200,289 shares (30-day average 293,225).
Data as of November 13, 2026.
13-Nov-2026
Business Wire (Mon, 9-Nov 7:30 AM ET)
AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London
Business Wire (Wed, 4-Nov 4:00 PM ET)
AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
Business Wire (Wed, 4-Nov 7:00 AM ET)
Business Wire (Mon, 2-Nov 7:00 AM ET)
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
Business Wire (Fri, 23-Oct 5:00 PM ET)
Business Wire (Wed, 21-Oct 7:00 AM ET)
PRNewswire (Mon, 12-Oct 8:51 AM ET)
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
Business Wire (Mon, 28-Sep 7:00 AM ET)
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
Business Wire (Wed, 16-Sep 5:33 PM ET)
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
An2 Therapeutics trades on the NASDAQ stock market under the symbol ANTX.
As of November 13, 2026, ANTX stock price climbed to $4.55 with 200,289 million shares trading.
ANTX has a beta of -0.46, meaning it tends to be less sensitive to market movements. ANTX has a correlation of 0.00 to the broad based SPY ETF.
ANTX has a market cap of $172.64 million. This is considered a Micro Cap stock.
In the last 3 years, ANTX traded as high as $22.22 and as low as $.87.
The top ETF exchange traded funds that ANTX belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
ANTX has outperformed the market in the last year with a price return of +302.7% while the SPY ETF gained +13.4%. However, in the short term, ANTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -23.9% vs -2.8% return in SPY. But in the last 2 weeks, ANTX shares have fared better than the market returning +0.4% compared to SPY -0.2%.
ANTX support price is $4.16 and resistance is $4.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANTX shares will trade within this expected range on the day.